TessArae LLC is responsible for the development and commercialization of comprehensive differential diagnostic technology for targeted sequencing applications in the fields of human genetic disease, microbial identification and infectious disease agents. TessAraeâs TessArray RPM (Resequencing Pathogen Microarray) technology simultaneously detects and identifies numerous pathogens from clinical and environmental samples, enabling characterization of multiple co-infecting pathogens and elucidation of novel sequence variants, all in a same day, single sample, multiple result test. TessArae technology began as a US Department of Defense (DOD) development project to create an assay with the ability to identify hundreds of epidemic or biothreat pathogens in a single sample circulating in military troops. After nearly $40 million of DOD funding, the resultant targeted sequencing technology was licensed in 2005 to the newly formed TessArae by its scientific architect, Dr. Clark Tibbetts, and the executive who oversaw the project for DOD, General Klaus Schafer. Since its inception, the company has designed fifteen custom assays for a wide variety of partners, including worldwide government agencies, academic institutions and commercial reference laboratories.
